Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.83Last Year’s EPS
-0.57Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 2.99%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call was overall optimistic with a strong focus on the successful approval and launch of VYKAT XR, which has been met with significant interest from both patients and prescribers. The financial outlook is stable with adequate reserves, though the company reported no revenue for Q1 2025 and an increased net loss.Company Guidance
During the Soleno Therapeutics first quarter 2025 earnings call, the company provided significant updates, notably the FDA approval and commercial launch of VYKAT XR for treating hyperphagia in individuals aged four and older with Prader-Willi syndrome (PWS). The company reported the receipt of 268 patient start forms within 29 business days post-approval and identified 131 unique prescribers, indicating strong early adoption. Soleno anticipates modest revenue initially, as patient scheduling and payer coverage policies develop. Financially, the company ended the quarter with $290 million in cash, cash equivalents, and marketable securities, down from $318.6 million at the end of 2024. Research and development expenses were $13.5 million, while selling, general, and administrative expenses rose to $29.3 million, reflecting pre-launch preparations. Soleno plans to submit a marketing authorization application to the European Medicines Agency in the first half of 2025, aiming to expand VYKAT XR's availability internationally.FDA Approval and Launch of VYKAT XR
FDA approved VYKAT XR for hyperphagia in Prader-Willi syndrome, and the commercial launch followed swiftly with patients receiving treatment ahead of schedule.
Strong Initial Launch Metrics
268 patient start forms received within 29 business days and 131 unique prescribers engaged, indicating strong initial interest and awareness.
Sufficient Financial Reserves
The company ended the quarter with $290 million in cash and believes it has sufficient funds to reach cash flow breakeven, with an additional $75 million available through a loan agreement.
Positive Payer and Market Feedback
Positive feedback from payers regarding the VYKAT XR value proposition, and anticipation of broad payer coverage in the U.S.
SLNO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SLNO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $74.66 | $76.26 | +2.14% |
Feb 27, 2025 | $44.99 | $48.82 | +8.51% |
Nov 06, 2024 | $56.86 | $57.11 | +0.44% |
Aug 07, 2024 | $43.96 | $45.08 | +2.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Soleno Therapeutics Inc (SLNO) report earnings?
Soleno Therapeutics Inc (SLNO) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Soleno Therapeutics Inc (SLNO) earnings time?
Soleno Therapeutics Inc (SLNO) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SLNO EPS forecast?
SLNO EPS forecast for the fiscal quarter 2025 (Q2) is -0.83.